查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085705

胃癌治療市場：2026-2032年全球市場預測（依治療分類、治療線、給藥途徑、劑型、治療方法及通路分類）

Gastric Cancer Drugs Market by Therapeutic Class, Treatment Line, Route Of Administration, Dosage Form, Therapy Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，胃癌治療市場規模將成長至 66.3 億美元，複合年成長率為 6.34%。

主要市場統計數據
基準年 2025 43.1億美元
預計年份：2026年 45.8億美元
預測年份 2032 66.3億美元
複合年成長率 (%) 6.34%

胃癌仍然是疾病負擔沉重的癌症領域，根據 GLOBOCAN 2022 估計，全球每年新增胃癌病例約 96.9 萬例，死亡病例約 66 萬例。這種疾病負擔推動了對胃癌治療的需求，涵蓋化療、標靶治療、免疫腫瘤學、抗血管生成療法以及新的生物標記導向療法。

商業格局正從標準化細胞毒性療法轉向精準醫療。隨著HER2、PD-L1複合陽性評分、MSI-H/dMMR、EBV狀態和CLDN18.2檢測結果對第一線及後續治療方案的選擇影響日益顯著，胃癌治療市場競爭異常激烈，臨床差異化、伴隨診斷、治療順序和真實世界療效是推動治療方案普及的關鍵因素。

胃癌治療格局的變革性變化

胃癌治療領域最顯著的變化是免疫療法和標靶治療在治療早期階段的日益普及。查核點抑制劑正在拓展晚期胃癌和胃食道交界處癌的治療選擇，尤其是在生物標記明確的患者群體中。同時，HER2標靶治療對於HER2陽性胃癌仍然至關重要，而化療在多種治療方案中也持續發揮核心作用。

人工智慧對胃癌治療藥物的累積影響

人工智慧 (AI) 透過加速標靶發現、臨床試驗匹配、患者分層、數位病理檢測和基於影像的療效評估，正在推動胃癌治療的發展。 AI 驅動的病理學和放射組學有助於識別生物標記表達模式、腫瘤異質性、免疫微環境訊號傳導，以及更可能從免疫療法或標靶治療中獲益的患者。

關於胃癌治療的關鍵區域見解

亞太地區是胃癌治療需求的流行病學中心，這主要受中國、日本、韓國和東南亞部分地區高發病率的驅動。已發表的癌症負擔數據顯示，東亞地區是胃癌高風險地區之一，日本和韓國的全國性篩檢計畫支持早期發現和系統性轉診途徑。同時，全部區域大量晚期患者的存在也凸顯了對全身性治療的需求，包括化療、免疫查核點抑制劑、HER2標靶治療、抗血管新生藥物和CLDN18.2標靶治療。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

東協市場正透過改善癌症診療基礎設施、提升診斷能力以及擴大系統性癌症治療的可及性而不斷擴張，但各成員國在晚期胃癌生物標記檢測和治療方面的可及性差異顯著。在海灣合作理事會（GCC）成員國，對專科癌症中心、數位醫療基礎設施和基因組醫學舉措的投資，正為高品質標靶治療、免疫腫瘤療法和伴隨診斷在胃癌治療中的應用創造有利環境。

主要國家胃癌藥物市場分析。

美國在快速引入FDA批准的胃癌療法、廣泛開展生物標記檢測和臨床試驗方面主導，這得益於以指南為基礎的癌症診療和完善的精準醫療基礎設施。加拿大則強調循證報銷、省級准入決定以及確保其地域分散的人口都能公平地獲得癌症治療。在墨西哥和巴西，隨著對私立癌症診療機構、三級癌症中心和公共衛生領域投資的增加，對免疫腫瘤學和標靶治療的需求日益成長，但分子診斷的醫療覆蓋範圍仍然不盡相同。

為胃癌治療行業的領導者提供的實用建議

產業領導者應優先考慮生物標記整合的研發策略，確保將HER2、PD-L1複合陽性評分、MSI-H/dMMR、EBV狀態和CLDN18.2的檢測納入臨床試驗設計、上市計畫、醫師教育和病患篩選流程。與診斷服務提供者、病理網路和癌症中心建立合作關係，可以減少治療延誤，提高合格患者的檢出率，並增強人們對生物標記驅動的胃癌療法的信心。

胃癌治療藥物分析的調查方法

本執行摘要基於檢驗的二手研究，包括公開的腫瘤學指南、監管公告、同行評審的臨床試驗數據、癌症流行病學資料庫、癌症登記出版物以及政府衛生資訊來源。流行病學框架反映了全球癌症統計數據，例如 GLOBOCAN 2022 以及來自權威公共衛生機構的疾病負擔報告。

結論：胃癌治療藥物的未來發展方向

隨著免疫療法、HER2標靶治療、抗血管新生療法和CLDN18.2標靶治療重塑胃癌治療標準，胃癌治療市場正進入一個更精準且競爭激烈的階段。全球高死亡率凸顯了早期診斷、更廣泛的生物標記檢測、更便捷的分子病理學檢測以及在晚期和局限性胃癌中更持久的治療反應的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 胃癌治療市場：依治療分類

  • 化療
    • Fluoropyrimidines藥物
    • 鉑類藥物
    • 紫杉烷類藥物
  • 免疫查核點抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
  • 標靶治療
    • HER2抑制劑
    • VEGF抑制劑

第8章：胃癌治療市場：依治療線分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第9章：胃癌治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：胃癌治療市場：依劑型分類

  • 膠囊
  • 凍乾粉
  • 注射液
  • 藥片

第11章：胃癌治療市場：依治療方法分類

  • 聯合治療
  • 單藥治療

第12章：胃癌治療市場：依通路分類

  • 醫院藥房
  • 零售藥房

第13章：胃癌治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 胃癌治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 胃癌治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines, Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hofmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • LES LABORATOIRES SERVIER
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical
  • Pfizer, Inc.
  • Prestige Biopharma
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceuticals Limited
  • Taiho Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-437E9896A4F6

The Gastric Cancer Drugs Market is projected to grow by USD 6.63 billion at a CAGR of 6.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.31 billion
Estimated Year [2026] USD 4.58 billion
Forecast Year [2032] USD 6.63 billion
CAGR (%) 6.34%

Gastric cancer remains a high-burden oncology field, with GLOBOCAN 2022 estimating about 969,000 new stomach cancer cases and nearly 660,000 deaths worldwide. This disease burden sustains demand for gastric cancer drugs across chemotherapy, targeted therapy, immuno-oncology, anti-angiogenic therapy, and emerging biomarker-directed regimens.

The commercial landscape is shifting from one-size-fits-all cytotoxic treatment toward precision medicine. HER2, PD-L1 combined positive score, MSI-H/dMMR, EBV status, and CLDN18.2 testing increasingly shape first-line and later-line therapy selection, positioning gastric cancer therapeutics as a competitive market where clinical differentiation, companion diagnostics, treatment sequencing, and real-world outcomes are central to adoption.

Transformative Shifts in the Gastric Cancer Treatment Landscape

The most important shift in gastric cancer treatment is the movement of immunotherapy and targeted therapy into earlier lines of care. Checkpoint inhibitors have expanded treatment options for advanced gastric and gastroesophageal junction cancers, particularly in biomarker-defined populations, while HER2-directed therapy remains essential for HER2-positive disease and chemotherapy continues to serve as a backbone across multiple treatment settings.

Another transformative change is the rise of CLDN18.2 as a validated target, supported by regulatory approvals in major markets for eligible HER2-negative gastric and gastroesophageal junction adenocarcinoma. This expands the landscape beyond traditional HER2 and PD-1 strategies and increases the importance of broad biomarker testing at diagnosis, multidisciplinary treatment planning, and evidence-based sequencing of gastric cancer drugs.

Cumulative Impact of Artificial Intelligence on Gastric Cancer Drugs

Artificial intelligence is strengthening gastric cancer drug development by accelerating target discovery, clinical trial matching, patient stratification, digital pathology review, and imaging-based response assessment. AI-enabled pathology and radiomics can help identify biomarker expression patterns, tumor heterogeneity, immune microenvironment signals, and patients more likely to benefit from immunotherapy or targeted agents.

The cumulative impact is operational as well as scientific. AI can improve clinical trial feasibility, optimize site selection in high-incidence regions, support adverse event detection through real-world data analytics, and refine evidence generation after launch. For industry leaders, responsible AI adoption can shorten development cycles while improving evidence quality, reproducibility, and patient selection across gastric cancer therapeutics.

Key Regional Insights for Gastric Cancer Drugs

Asia-Pacific is the epidemiological center of gastric cancer drugs demand, driven by high incidence in China, Japan, South Korea, and parts of Southeast Asia. Publicly reported cancer burden data consistently show Eastern Asia as one of the highest-risk regions for stomach cancer, while national screening programs in Japan and South Korea support earlier detection and structured referral pathways. At the same time, large advanced-stage patient populations across the region sustain the need for systemic therapies, including chemotherapy, immune checkpoint inhibitors, HER2-directed therapy, anti-angiogenic agents, and CLDN18.2-targeted treatment.

North America demonstrates strong adoption of biomarker-led gastric cancer treatment due to mature oncology infrastructure, broad clinical trial participation, molecular testing availability, and guideline-driven care pathways. Europe similarly benefits from coordinated regulatory standards, established cancer networks, and reimbursement assessments that increasingly consider companion diagnostics, survival outcomes, toxicity profiles, and quality-of-life evidence. In Latin America, gastric cancer drug adoption is supported by rising oncology investment and growing private-sector access, although public reimbursement and molecular testing availability remain uneven across countries.

The Middle East is advancing through investment in specialized cancer centers, genomic medicine programs, and referral networks, creating opportunities for precision oncology drugs and companion diagnostic integration. Africa faces a more fragmented access environment, with late-stage diagnosis, limited pathology capacity, and affordability constraints influencing uptake of novel gastric cancer therapeutics. Across all regions, the strongest opportunities are linked to earlier diagnosis, scalable biomarker testing, equitable access models, and evidence that supports treatment value in real-world clinical practice.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding through improving oncology infrastructure, rising diagnostic capacity, and broader access to systemic cancer treatment, although availability of biomarker testing and advanced gastric cancer drugs varies significantly across member countries. The GCC is investing in specialized cancer centers, digital health infrastructure, and genomic medicine initiatives, creating favorable conditions for premium targeted therapies, immuno-oncology regimens, and companion diagnostics in gastric cancer care.

The European Union benefits from centralized regulatory review, health technology assessment processes, and strong clinical guideline alignment, supporting consistent evidence standards across member states while still reflecting country-level reimbursement differences. BRICS countries represent a large clinical demand base, led by China and India in patient volume and by expanding oncology research capacity across the group. These markets are increasingly important for clinical trial recruitment, local manufacturing strategies, and access programs designed for high-burden cancer populations.

G7 markets remain key launch territories for innovative gastric cancer drugs because of advanced oncology systems, robust regulatory frameworks, precision medicine adoption, and high levels of specialist care access. NATO countries overlap with several high-income healthcare systems where oncology access, medicine supply resilience, and health security are strategic priorities. Across ASEAN, GCC, the European Union, BRICS, G7, and NATO, industry success depends on aligning evidence generation with local reimbursement expectations, diagnostic readiness, and national cancer-control priorities.

Key Country Insights in Major Gastric Cancer Drug Markets

The United States leads in rapid adoption of FDA-approved gastric cancer drugs, broad biomarker testing, and clinical trial activity, supported by guideline-based oncology practice and high availability of precision medicine infrastructure. Canada emphasizes evidence-based reimbursement, provincial access decisions, and equitable delivery of cancer medicines across geographically dispersed populations. Mexico and Brazil show increasing demand for immuno-oncology and targeted drugs, supported by expanding private oncology care, tertiary cancer centers, and public health investments, although molecular diagnostic coverage remains variable.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are central to clinical research, guideline-led treatment adoption, and health technology assessment of novel gastric cancer drugs. Germany and France maintain strong specialist oncology networks, the United Kingdom emphasizes evidence-based access and national treatment guidance, while Italy and Spain combine academic oncology activity with structured regional cancer care. Russia remains an important patient population but faces variability in access to innovative therapies, diagnostic infrastructure, and regional oncology resources.

China, India, Japan, Australia, and South Korea are pivotal Asia-Pacific markets for gastric cancer therapeutics. China combines large patient volumes with expanding domestic oncology innovation and increasing biomarker testing capacity, while India offers substantial clinical scale but continues to face access, affordability, and pathology infrastructure challenges. Japan and South Korea have advanced screening systems, high clinical expertise, and strong adoption of evidence-based gastric cancer treatment, making them influential in regional standards of care. Australia maintains strong precision oncology capabilities, clinical trial networks, and structured reimbursement assessment for innovative cancer medicines.

Actionable Recommendations for Gastric Cancer Drug Industry Leaders

Industry leaders should prioritize biomarker-integrated development strategies, ensuring that HER2, PD-L1 combined positive score, MSI-H/dMMR, EBV status, and CLDN18.2 testing are embedded in trial design, launch planning, physician education, and patient identification workflows. Partnerships with diagnostic providers, pathology networks, and cancer centers can reduce treatment delays, improve eligible patient detection, and strengthen confidence in biomarker-directed gastric cancer drugs.

Organizations should also expand real-world evidence programs to demonstrate survival, tolerability, treatment sequencing value, quality-of-life outcomes, and cost-effectiveness across diverse healthcare settings. A differentiated access strategy is essential, with value-based evidence packages for mature markets and tiered pricing, local partnerships, diagnostic capacity-building, and patient support initiatives for emerging regions with high gastric cancer burden. Leaders should further invest in AI-enabled trial operations, regional clinical trial diversity, and post-approval evidence generation to sustain competitive positioning.

Research Methodology for Gastric Cancer Drugs Analysis

This executive summary is developed from verified secondary research, including publicly available oncology guidelines, regulatory announcements, peer-reviewed clinical trial data, cancer epidemiology databases, cancer registry publications, and government health sources. Epidemiological framing reflects global cancer statistics such as GLOBOCAN 2022 and disease-burden reporting from recognized public health organizations.

Market interpretation applies triangulation across clinical evidence, regulatory approvals, biomarker trends, regional treatment access, cancer screening practices, reimbursement frameworks, and healthcare infrastructure. The methodology emphasizes data-backed insights, cross-validation of therapeutic trends, and qualitative assessment of commercialization dynamics in the gastric cancer drugs landscape, while avoiding market estimation, market sizing, market share, and forecasting.

Conclusion: Future Direction for Gastric Cancer Drugs

The gastric cancer drugs landscape is entering a more precise and competitive phase as immunotherapy, HER2-directed therapy, anti-angiogenic therapy, and CLDN18.2-targeted treatment reshape standards of care. High global mortality underscores the need for earlier diagnosis, broader biomarker testing, improved access to molecular pathology, and more durable treatment responses in both advanced and localized disease settings.

Future leadership will depend on clinical differentiation, diagnostic integration, regional access execution, and evidence generation across diverse patient populations. Stakeholders that align innovation with affordability, real-world outcomes, companion diagnostic readiness, and local cancer-control priorities will be better positioned to improve treatment adoption and patient outcomes in gastric cancer therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastric Cancer Drugs Market, by Therapeutic Class

  • 7.1. Chemotherapy
    • 7.1.1. Fluoropyrimidines
    • 7.1.2. Platinum-Based Agents
    • 7.1.3. Taxanes
  • 7.2. Immune Checkpoint Inhibitors
    • 7.2.1. PD-1 Inhibitors
    • 7.2.2. PD-L1 Inhibitors
  • 7.3. Targeted Therapy
    • 7.3.1. HER2 Inhibitors
    • 7.3.2. VEGF Inhibitors

8. Gastric Cancer Drugs Market, by Treatment Line

  • 8.1. First Line
  • 8.2. Second Line
  • 8.3. Third Line Or Later

9. Gastric Cancer Drugs Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Gastric Cancer Drugs Market, by Dosage Form

  • 10.1. Capsules
  • 10.2. Lyophilized Powder
  • 10.3. Injectable Solution
  • 10.4. Tablets

11. Gastric Cancer Drugs Market, by Therapy Type

  • 11.1. Combination Therapy
  • 11.2. Monotherapy

12. Gastric Cancer Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Retail Pharmacies

13. Gastric Cancer Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Gastric Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gastric Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Amgen Inc.
  • 17.2. Astellas Pharma Inc.
  • 17.3. AstraZeneca PLC
  • 17.4. Bayer AG
  • 17.5. BeOne Medicines, Ltd.
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Bristol-Myers Squibb Company
  • 17.8. Cipla Limited
  • 17.9. Eli Lilly and Company
  • 17.10. F. Hofmann-La Roche Ltd.
  • 17.11. Gilead Sciences, Inc.
  • 17.12. GlaxoSmithKline PLC
  • 17.13. Incyte Corporation
  • 17.14. Ipsen Pharma
  • 17.15. LES LABORATOIRES SERVIER
  • 17.16. Merck & Co., Inc.
  • 17.17. Novartis AG
  • 17.18. Ono Pharmaceutical
  • 17.19. Pfizer, Inc.
  • 17.20. Prestige Biopharma
  • 17.21. Sanofi SA
  • 17.22. Sumitomo Pharma Co., Ltd.
  • 17.23. Sun Pharmaceuticals Limited
  • 17.24. Taiho Pharmaceutical Co., Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GASTRIC CANCER DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GASTRIC CANCER DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GASTRIC CANCER DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GASTRIC CANCER DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GASTRIC CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL GASTRIC CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FLUOROPYRIMIDINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLATINUM-BASED AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLATINUM-BASED AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLATINUM-BASED AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TAXANES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TAXANES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TAXANES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PD-1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HER2 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HER2 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HER2 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VEGF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VEGF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VEGF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD LINE OR LATER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD LINE OR LATER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THIRD LINE OR LATER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INJECTABLE SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 160. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. G7 GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. NATO GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 198. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 200. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NATO GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL GASTRIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 219. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 221. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CANADA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 228. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 229. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 231. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MEXICO GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 237. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 239. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 240. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 241. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRAZIL GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 259. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 260. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 261. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 277. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 279. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 296. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 313. INDIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 323. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA GASTRIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA GASTRIC CANCER DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH